JP2020519635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519635A5 JP2020519635A5 JP2019562349A JP2019562349A JP2020519635A5 JP 2020519635 A5 JP2020519635 A5 JP 2020519635A5 JP 2019562349 A JP2019562349 A JP 2019562349A JP 2019562349 A JP2019562349 A JP 2019562349A JP 2020519635 A5 JP2020519635 A5 JP 2020519635A5
- Authority
- JP
- Japan
- Prior art keywords
- gel composition
- group
- composition according
- sorbitan
- sucrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 96
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 claims description 28
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 235000002639 sodium chloride Nutrition 0.000 claims description 27
- 229930006000 Sucrose Natural products 0.000 claims description 23
- 239000003349 gelling agent Substances 0.000 claims description 23
- 239000005720 sucrose Substances 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 22
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 20
- 239000003960 organic solvent Substances 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 230000009881 electrostatic interaction Effects 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000012456 homogeneous solution Substances 0.000 claims description 5
- 239000002086 nanomaterial Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 4
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 235000011148 calcium chloride Nutrition 0.000 claims description 4
- 229960001747 cinchocaine Drugs 0.000 claims description 4
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims description 4
- 229960004194 lidocaine Drugs 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 235000011147 magnesium chloride Nutrition 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 229960004919 procaine Drugs 0.000 claims description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 4
- 229960002372 tetracaine Drugs 0.000 claims description 4
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 239000011592 zinc chloride Substances 0.000 claims description 4
- 235000005074 zinc chloride Nutrition 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000005538 encapsulation Methods 0.000 claims description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 3
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 3
- 239000012498 ultrapure water Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229940049964 oleate Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 230000009974 thixotropic effect Effects 0.000 claims description 2
- 239000003589 local anesthetic agent Substances 0.000 claims 9
- 239000001488 sodium phosphate Substances 0.000 claims 6
- 229960005015 local anesthetics Drugs 0.000 claims 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 4
- 235000019799 monosodium phosphate Nutrition 0.000 claims 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 4
- 125000002091 cationic group Chemical group 0.000 claims 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 2
- 235000019800 disodium phosphate Nutrition 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims 2
- 239000002953 phosphate buffered saline Substances 0.000 claims 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- 150000003512 tertiary amines Chemical group 0.000 claims 2
- 239000007863 gel particle Substances 0.000 claims 1
- 238000001338 self-assembly Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 description 64
- 239000003795 chemical substances by application Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 5
- 230000003444 anaesthetic effect Effects 0.000 description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- -1 Ascorbyl laurat Chemical compound 0.000 description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
- 229960005274 benzocaine Drugs 0.000 description 2
- 229960003150 bupivacaine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022080798A JP2022103299A (ja) | 2017-05-08 | 2022-05-17 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2023014533A JP2023041861A (ja) | 2017-05-08 | 2023-02-02 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2023173522A JP2023168587A (ja) | 2017-05-08 | 2023-10-05 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502872P | 2017-05-08 | 2017-05-08 | |
| US62/502,872 | 2017-05-08 | ||
| PCT/US2018/031654 WO2018208822A1 (en) | 2017-05-08 | 2018-05-08 | Formulation of nanostructured gels for increased agent loading and adhesion |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022080798A Division JP2022103299A (ja) | 2017-05-08 | 2022-05-17 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020519635A JP2020519635A (ja) | 2020-07-02 |
| JP2020519635A5 true JP2020519635A5 (https=) | 2021-05-27 |
| JP7211974B2 JP7211974B2 (ja) | 2023-01-24 |
Family
ID=62223333
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019562349A Active JP7211974B2 (ja) | 2017-05-08 | 2018-05-08 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2022080798A Pending JP2022103299A (ja) | 2017-05-08 | 2022-05-17 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2023014533A Pending JP2023041861A (ja) | 2017-05-08 | 2023-02-02 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2023173522A Pending JP2023168587A (ja) | 2017-05-08 | 2023-10-05 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022080798A Pending JP2022103299A (ja) | 2017-05-08 | 2022-05-17 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2023014533A Pending JP2023041861A (ja) | 2017-05-08 | 2023-02-02 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
| JP2023173522A Pending JP2023168587A (ja) | 2017-05-08 | 2023-10-05 | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10881745B2 (https=) |
| EP (1) | EP3621594A1 (https=) |
| JP (4) | JP7211974B2 (https=) |
| AU (2) | AU2018266131B2 (https=) |
| CA (1) | CA3061480A1 (https=) |
| WO (1) | WO2018208822A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3136635A1 (en) * | 2019-04-11 | 2020-10-15 | Convatec Technologies Inc. | Superporous hydrogels, methods of making the same, and articles incorporating the same |
| CN111781128B (zh) * | 2020-06-15 | 2023-07-07 | 迪瑞医疗科技股份有限公司 | 一种尿分析仪用鞘液及其制备方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2417494A1 (fr) | 1978-02-16 | 1979-09-14 | Bottu | Nouvelles compositions analgesiques et antipyretiques contenant un derive de paracetamol |
| AU653026B2 (en) | 1991-06-07 | 1994-09-15 | Teikoku Seiyaku Kabushiki Kaisha | Physiologically active polypeptide-containing pharmaceutical composition |
| GB9403857D0 (en) | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
| ATE221086T1 (de) * | 1995-11-15 | 2002-08-15 | Seikagaku Kogyo Co Ltd | Photovernetztes hyaluronsäuregel und verfahren zu dessen herstellung |
| CA2212300A1 (en) | 1997-08-04 | 1999-02-04 | Abdellatif Chenite | In vitro or in vivo gelfying chitosan and therapeutic uses thereof |
| BE1011899A6 (fr) | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| FR2794998B1 (fr) | 1999-06-21 | 2001-07-27 | Oreal | Organogels et leurs utilisations notamment cosmetiques |
| US7179784B2 (en) | 2001-07-10 | 2007-02-20 | Massachusetts Institute Of Technology | Surfactant peptide nanostructures, and uses thereof |
| US20050084470A1 (en) | 2003-10-15 | 2005-04-21 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Skin care and cleansing compositions containing oil seed product |
| DE602004031301D1 (de) | 2003-11-12 | 2011-03-17 | Applied Nanosystems Bv | Nichtsymmetrisches geliermittel |
| US7544661B2 (en) | 2003-12-05 | 2009-06-09 | Northwestern University | Self-assembling peptide amphiphiles and related methods for growth factor delivery |
| WO2005097828A2 (en) * | 2004-04-01 | 2005-10-20 | Board Of Regents, The University Of Texas System | Peptides of cav2.2 that inhibit pain |
| DE602005010424D1 (de) | 2004-06-03 | 2008-11-27 | Bracco Research Sa | Liposomale anordnung für die therapeutische und/oder diagnostische anwendung |
| FR2871701B1 (fr) | 2004-06-21 | 2006-09-22 | Centre Nat Rech Scient Cnrse | Biomateriaux bioactifs pour le relarguage controle de principes actifs |
| US7854943B2 (en) * | 2004-06-24 | 2010-12-21 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| EP1800694A1 (en) | 2005-12-23 | 2007-06-27 | Applied NanoSystems B.V. | Controlled release gels |
| US7988883B2 (en) * | 2006-02-10 | 2011-08-02 | Dupont Tate & Lyle Bio Products Company, Llc | Heat transfer compositions comprising renewably-based biodegradable 1,3-propanediol |
| WO2007095255A2 (en) * | 2006-02-10 | 2007-08-23 | Dupont Tate & Lyle Bio Products Company, Llc | Biodegradable compositions comprising renewably-based, biodegradable 1.3-propanediol |
| US8968784B2 (en) | 2006-05-22 | 2015-03-03 | Research Foundation Of The City University Of New York | Method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery |
| US20080021068A1 (en) * | 2006-07-24 | 2008-01-24 | Akorn, Inc. | Aqueous gel formulation and method for inducing topical anesthesia |
| JP5358574B2 (ja) | 2007-08-17 | 2013-12-04 | アルション セラピューティクス， インコーポレイテッド | 高濃度の局所麻酔薬調合物 |
| US8329220B2 (en) | 2007-08-24 | 2012-12-11 | Aegis Therapeutics, Llc | Controlled release formulations |
| US20090263489A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation |
| WO2010033726A2 (en) | 2008-09-17 | 2010-03-25 | The Brigham And Women's Hospital, Inc. | Drug delivery composition comprising a self-assembled gelator |
| JP5724108B2 (ja) * | 2009-04-22 | 2015-05-27 | メドスキン ソリューションズ ドクター ズベラック アーゲーＭｅｄＳｋｉｎ Ｓｏｌｕｔｉｏｎｓ Ｄｒ．Ｓｕｗｅｌａｃｋ ＡＧ | 凍結乾燥組成物 |
| AU2015200633A1 (en) * | 2009-05-04 | 2015-02-26 | Zars Pharma, Inc. | Methods for treating pains associated with neuroma, nerve entrapment, and other conditions |
| CA2770490C (en) * | 2009-08-11 | 2024-04-16 | The Johns Hopkins University | Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products |
| US9693976B2 (en) * | 2010-01-14 | 2017-07-04 | Crescita Therapeutics Inc. | Solid-forming local anesthetic formulations for pain control |
| EP2361640A1 (en) | 2010-02-25 | 2011-08-31 | Université de Liège | Cell cultivation in chitosan alginate hydrogel beads |
| KR20130080435A (ko) * | 2010-04-01 | 2013-07-12 | 파마네스트 아베 | 국소마취의 생체 점착성 조성물 |
| BR112013008697A2 (pt) * | 2010-09-24 | 2016-06-21 | Massachusetts Inst Technology | géis nanoestruturados capazes de liberação controlada de agentes encapsulados |
| GB201020193D0 (en) | 2010-11-29 | 2011-01-12 | Biotec Pharmacon Asa | Glucan compositions |
| ES2390428B1 (es) * | 2011-04-15 | 2013-10-01 | Universidad De Almería | Preparado de bacterias probióticas para su administración oral a peces cultivados basado en la encapsulación en hidrogeles de alginato. |
| JP6274440B2 (ja) | 2012-06-25 | 2018-02-07 | 日産化学工業株式会社 | 分散液及びヒドロゲル形成方法 |
| US20150246065A1 (en) | 2012-09-14 | 2015-09-03 | Cipla Limited | Topical Pharmaceutical Composition |
| WO2014089472A1 (en) | 2012-12-07 | 2014-06-12 | Kansas State University Research Foundation | Peptide-albumin hydrogel properties and its applications |
| HK1218858A1 (zh) | 2013-03-14 | 2017-03-17 | 麻省理工学院 | 用於长时间持续释放人类抗体的多层可注射自组装肽脚手架水凝胶 |
| US9789073B2 (en) * | 2013-03-14 | 2017-10-17 | Pathak Holdings, Llc | Compositions, methods and devices for local drug delivery |
| US20150297731A1 (en) * | 2014-04-21 | 2015-10-22 | National Yang-Ming University | Thermosensitive injectable glaucoma drug carrier gel and the fabricating method thereof |
| US9452178B1 (en) * | 2014-10-22 | 2016-09-27 | SatisPharma, LLC | Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations |
| WO2016098057A1 (en) * | 2014-12-17 | 2016-06-23 | Socovar, L.P. | Chitosan-based hydrogel and applications thereof |
| EP4279064A3 (en) * | 2015-05-12 | 2024-02-28 | Incept, LLC | Drug delivery from hydrogels |
| US9962339B2 (en) * | 2015-10-08 | 2018-05-08 | The Brigham And Women's Hospital, Inc. | Stabilized assembled nanostructures for delivery of encapsulated agents |
| EP3452094B1 (en) * | 2016-05-06 | 2021-11-17 | The Brigham and Women's Hospital, Inc. | Binary self assembled gels for controlled delivery of encapsulated agents to cartilage |
| CA3062885C (en) * | 2016-05-06 | 2022-03-29 | The Brigham And Women's Hospital, Inc. | Self-assembled gels for controlled delivery of biologics and labile agents |
| US20180050055A1 (en) * | 2016-08-16 | 2018-02-22 | Hafiz Ahmed | Exploiting nutrient deprivation for modulation of glycosylation - research diagnostic, therapeutic, and biotechnology applications |
| EP3335695B1 (en) * | 2016-12-15 | 2020-02-05 | UPM-Kymmene Corporation | A method for freeze-drying hydrogel comprising nanofibrillar cellulose, a freeze-dried medical hydrogel comprising nanofibrillar cellulose, and a hydrogel comprising nanofibrillar cellulose |
-
2018
- 2018-05-08 US US15/974,535 patent/US10881745B2/en not_active Expired - Fee Related
- 2018-05-08 WO PCT/US2018/031654 patent/WO2018208822A1/en not_active Ceased
- 2018-05-08 CA CA3061480A patent/CA3061480A1/en active Pending
- 2018-05-08 AU AU2018266131A patent/AU2018266131B2/en not_active Ceased
- 2018-05-08 EP EP18726703.4A patent/EP3621594A1/en not_active Withdrawn
- 2018-05-08 JP JP2019562349A patent/JP7211974B2/ja active Active
-
2020
- 2020-12-30 US US17/137,931 patent/US20210196836A1/en not_active Abandoned
-
2021
- 2021-09-28 AU AU2021240143A patent/AU2021240143B2/en not_active Expired - Fee Related
-
2022
- 2022-05-17 JP JP2022080798A patent/JP2022103299A/ja active Pending
-
2023
- 2023-02-02 JP JP2023014533A patent/JP2023041861A/ja active Pending
- 2023-10-05 JP JP2023173522A patent/JP2023168587A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gavini et al. | Spray-dried microspheres based on methylpyrrolidinone chitosan as new carrier for nasal administration of metoclopramide | |
| CN1162148C (zh) | 含有纤维素醚的热凝胶药物转运载体 | |
| CN105597146A (zh) | 伤口愈合用多功能温敏凝胶复合物敷料及其制备与使用方法 | |
| CN111447920A (zh) | 具有高活性物质负载量的口服薄膜 | |
| WO2014039012A1 (en) | Hyaluronic acid-based drug delivery systems | |
| RU2016151163A (ru) | Композиции, включающие электрогидродинамически полученные волокна, для нанесения заданных доз активного вещества на кожу или слизистую оболочку | |
| CN104888224A (zh) | 一种两亲性多糖衍生物/泊洛沙姆温敏型原位水凝胶及其制备方法 | |
| RU2018109496A (ru) | Фармацевтическая композиция, содержащая электрогидродинамически полученные волокна, композиция, имеющая улучшенное время удержания в месте применения | |
| CN103491961B (zh) | 阿立哌唑组合物和用于其经皮给药的方法 | |
| CN104136012A (zh) | 制备装载有活性物质的纳米颗粒的方法 | |
| CN114983930B (zh) | 基于高分子聚合物的ros响应型脑靶向纳米凝胶双层释药系统及其制备方法和应用 | |
| CN108721207A (zh) | 氨基化泊洛沙姆衍生物温度敏感型即型凝胶剂及其制备方法 | |
| JP2021520352A5 (https=) | ||
| KR20170106460A (ko) | 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제 | |
| CN110638752A (zh) | 注射剂 | |
| Rad et al. | Application of thermo-responsive polymers as smart biomaterials in wound dressing | |
| JP2015515968A5 (https=) | ||
| JP2019516689A5 (https=) | ||
| CN106693042B (zh) | 一种抗菌水凝胶敷料及制备方法 | |
| KR20090014205A (ko) | 현탁성 히드로겔과 그의 제조 방법 | |
| JP2020519635A5 (https=) | ||
| JP2023168587A (ja) | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 | |
| KR101723724B1 (ko) | 수분감응성 겔이 도포된 야누스패브릭을 포함하는 구강점막용 또는 경피흡수용 패치 | |
| Milkova et al. | Nanocolloids of indomethacin prepared using sonication and subsequent encapsulation with polysaccharide films | |
| US20100297202A1 (en) | Planar antenna and method of manufacturing the same |